Young-Uk Cho

Young-Uk Cho

Auto-generated profile, based on publicly available information

Young-Uk Cho

Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Blood Research
Verified
Journal Article
Open access
PDF file
YCYoung-Uk Cho
Young-Uk Cho
Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical laboratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia consider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.

6 December 2017 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
SLSeung Hun Lee
Seung Hun Lee
SPSe Yoon Park
Se Yoon Park
MJMi Jin Jang
Mi Jin Jang
KCKi Ju Choi
Ki Ju Choi
HLHae Kyung Lee
Hae Kyung Lee
SHSeon Do Hwang
Seon Do Hwang
We report the first isolation of Anaplasma phagocytophilum in South Korea. A 61-year-old woman presented with a 6-day history of fever, headache, and myalgia. Initial investigation showed neutropenia and thrombocytopenia. We diagnosed human granulocytic anaplasmosis by microscopic examination and serologic testing. The patient recovered fully without antibiotic therapy. The isolate was obtained from the patient’s blood by cell culture and mouse inoculation. Its identity was confirmed by an immunofluorescence assay, sequencing of the 16S rRNA gene, msp2 (p44), and ankA genes, and staining and electron microscopy of morulae of A. phagocytophilum in cultured human promyelocytic leukemia HL-60 cells.

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BKBohyun Kim
Bohyun Kim
YCYoung-Uk Cho
Young-Uk Cho
MBMI HYUN BAE
MI HYUN BAE
SJSeongsoo Jang
Seongsoo Jang
ESEul-Ju Seo
Eul-Ju Seo
CPChan-Jeoung Park
Chan-Jeoung Park
Kim BH, et al. J Korean Med Sci. 2015 Jul;30(7):882-888. https://doi.org/10.3346/jkms.2015.30.7.882

30 May 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MLMin Young Lee
Min Young Lee
CPChan-Jeoung Park
Chan-Jeoung Park
YCYoung-Uk Cho
Young-Uk Cho
EYEunkyoung You
Eunkyoung You
SJSeongsoo Jang
Seongsoo Jang
JLJe-Hwan Lee
Je-Hwan Lee

4 January 2018 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
YCY.‐U. Cho
Y.‐U. Cho
EYE. You
E. You
SJS. Jang
S. Jang
CPC.‐J. Park
C.‐J. Park

8 April 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
SPSang Hyuk Park
Sang Hyuk Park
EYEunkyoung You
Eunkyoung You
CPChan-Jeoung Park
Chan-Jeoung Park
YCYoung‐Uk Cho
Young‐Uk Cho
SJSeongsoo Jang
Seongsoo Jang
JLJung‐Hee Lee
Jung‐Hee Lee
Background: We analyzed expression profiles of immune checkpoint receptors on T cell subsets and ligands on leukemic blasts in patients with B‐lymphoblastic leukemia (B‐ALL).Methods: Total 149 bone marrow (BM) samples obtained from 65 B‐ALL patients with four different clinical status (41 at diagnosis, 54 in complete remission [CR], 34 in persistence, and 20 in relapse), and 32 BM control samples were prospectively enrolled. Expression of immune checkpoint receptor (programmed cell death protein‐1 [PD‐1]) on T cell subsets and ligands (PD‐L1, PD‐L2) on leukemic blasts was evaluated by flow cytometry, and was compared between patient subgroups.Results: Relapsed patients demonstrated highest PD‐1 expression proportion and intensity on CD3+CD4+ T cells with statistical significance when compared to patients in persistence/CR/BM controls (p = .027/<.001/<.001 and .012/.001/<.001, respectively). Newly diagnosed patients showed significantly lower PD‐1 expression proportion on CD3+CD4+ T cells than relapsed patients (p < .001), but their intensity was not significantly different. Relapsed patients showed significantly higher PD‐1 expression proportion and intensity on CD3+CD8+ T cells than patients in CR/BM controls (p = .022/.045 and .049/.005, respectively), but PD‐1 expression status on them were not significantly different between relapsed and newly diagnosed patients. PD‐L1/L2 expression on leukemic blasts was not significantly different between patient subgroups.Conclusions: In BM aspirates from B‐ALL patients, PD‐1 expression on T‐cell subsets is increased at diagnosis, and to a greater extent, at relapse. These data suggest the potential usefulness of PD‐1 blockade in the treatment of B‐ALL, particularly at relapse.